Frequent messaging improves diabetes management

Communication between patients and providers through secure patient portals offers an extension of care. A study published in Diabetes Care showed patients with diabetes using secure messaging for medical advice have improved levels of management.

Patients with diabetes were enrolled in an online portal of an outpatient healthcare organization from 2011 to 2014 where researchers examined whether communication from physicians to patients resulted in less in-person visits and improve diabetes management.

This study, led by Sukyung Chung, PhD, from the Palo Alto Medical Foundation Research Institute in California, analyzed the correlations between messaging services providing chronic disease management education and diabetes quality measures. Results found that 72 percent of patients used messaging, and patients were more likely to use messaging with frequent visits. The more visits a patient attended, the less likely they were to meet blood sugar targets. The more frequent the messaging, the better the outcomes for diabetes management.  

“Patients with diabetes frequently used secure messaging for medical advice in addition to routine visits to care providers,” concluded Chung and colleagues. “Messaging was positively associated with better diabetes management in a large community outpatient practice.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.